JP7333815B2 - 肝臓機能改善用組成物 - Google Patents
肝臓機能改善用組成物 Download PDFInfo
- Publication number
- JP7333815B2 JP7333815B2 JP2021520792A JP2021520792A JP7333815B2 JP 7333815 B2 JP7333815 B2 JP 7333815B2 JP 2021520792 A JP2021520792 A JP 2021520792A JP 2021520792 A JP2021520792 A JP 2021520792A JP 7333815 B2 JP7333815 B2 JP 7333815B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- group
- liver function
- resorcinolic
- improving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 59
- 230000003908 liver function Effects 0.000 title claims description 38
- 241000196324 Embryophyta Species 0.000 claims description 34
- 150000002632 lipids Chemical class 0.000 claims description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 20
- 208000006454 hepatitis Diseases 0.000 claims description 18
- 210000004185 liver Anatomy 0.000 claims description 18
- -1 pharmaceutical Substances 0.000 claims description 16
- 208000024891 symptom Diseases 0.000 claims description 16
- 229930188104 Alkylresorcinol Natural products 0.000 claims description 15
- 231100000283 hepatitis Toxicity 0.000 claims description 15
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 14
- 208000002353 alcoholic hepatitis Diseases 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 10
- 241000209140 Triticum Species 0.000 claims description 7
- 235000021307 Triticum Nutrition 0.000 claims description 7
- 238000009825 accumulation Methods 0.000 claims description 7
- 150000003626 triacylglycerols Chemical class 0.000 claims description 7
- 235000013373 food additive Nutrition 0.000 claims description 6
- 239000002778 food additive Substances 0.000 claims description 6
- 239000013589 supplement Substances 0.000 claims description 6
- 235000020985 whole grains Nutrition 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 241000209504 Poaceae Species 0.000 claims description 2
- 238000012360 testing method Methods 0.000 description 39
- 210000005228 liver tissue Anatomy 0.000 description 29
- 230000000694 effects Effects 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000000605 extraction Methods 0.000 description 15
- 125000000217 alkyl group Chemical group 0.000 description 14
- 239000003921 oil Substances 0.000 description 12
- 108010016731 PPAR gamma Proteins 0.000 description 11
- IRMPFYJSHJGOPE-UHFFFAOYSA-N olivetol Chemical compound CCCCCC1=CC(O)=CC(O)=C1 IRMPFYJSHJGOPE-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 9
- 108010082126 Alanine transaminase Proteins 0.000 description 9
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 9
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000003925 fat Substances 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 210000003470 mitochondria Anatomy 0.000 description 8
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 7
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 7
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 7
- 235000021283 resveratrol Nutrition 0.000 description 7
- 229940016667 resveratrol Drugs 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 101001123331 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Proteins 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000010998 test method Methods 0.000 description 6
- 108010076365 Adiponectin Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 102100028960 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Human genes 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 108020005196 Mitochondrial DNA Proteins 0.000 description 4
- 102000023984 PPAR alpha Human genes 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- PUNOCEUUYUXUGR-UHFFFAOYSA-N 5-Nonadecyl-1,3-benzenediol Chemical compound CCCCCCCCCCCCCCCCCCCC1=CC(O)=CC(O)=C1 PUNOCEUUYUXUGR-UHFFFAOYSA-N 0.000 description 3
- BBGNINPPDHJETF-UHFFFAOYSA-N 5-heptadecylresorcinol Chemical compound CCCCCCCCCCCCCCCCCC1=CC(O)=CC(O)=C1 BBGNINPPDHJETF-UHFFFAOYSA-N 0.000 description 3
- QENPJKGENOZEEJ-UHFFFAOYSA-N 5-heptylbenzene-1,3-diol Chemical compound CCCCCCCC1=CC(O)=CC(O)=C1 QENPJKGENOZEEJ-UHFFFAOYSA-N 0.000 description 3
- OYXWBGYHDYVIDT-UHFFFAOYSA-N 5-nonylbenzene-1,3-diol Chemical compound CCCCCCCCCC1=CC(O)=CC(O)=C1 OYXWBGYHDYVIDT-UHFFFAOYSA-N 0.000 description 3
- SXRLJXDYAKBNRZ-UHFFFAOYSA-N 5-undecylbenzene-1,3-diol Chemical compound CCCCCCCCCCCC1=CC(O)=CC(O)=C1 SXRLJXDYAKBNRZ-UHFFFAOYSA-N 0.000 description 3
- 102000011690 Adiponectin Human genes 0.000 description 3
- UXOGOSLLGMYCNL-UHFFFAOYSA-N Grevillol Chemical compound CCCCCCCCCCCCCC1=CC(O)=CC(O)=C1 UXOGOSLLGMYCNL-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- KVVSCMOUFCNCGX-UHFFFAOYSA-N cardol Chemical compound CCCCCCCCCCCCCCCC1=CC(O)=CC(O)=C1 KVVSCMOUFCNCGX-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000002824 peroxisome Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- BLHLKJLSYHEOGY-UHFFFAOYSA-N 5-Heneicosyl-1,3-benzenediol Chemical compound CCCCCCCCCCCCCCCCCCCCCC1=CC(O)=CC(O)=C1 BLHLKJLSYHEOGY-UHFFFAOYSA-N 0.000 description 2
- GDJMJAKVVSGNLA-UHFFFAOYSA-N 5-Pentacosyl-1,3-benzenediol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC1=CC(O)=CC(O)=C1 GDJMJAKVVSGNLA-UHFFFAOYSA-N 0.000 description 2
- LNHZINSBVLHRFL-UHFFFAOYSA-N 5-heptacosylbenzene-1,3-diol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCC1=CC(O)=CC(O)=C1 LNHZINSBVLHRFL-UHFFFAOYSA-N 0.000 description 2
- OHTBGMREZYLZQD-UHFFFAOYSA-N 5-tricosylresorcinol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC1=CC(O)=CC(O)=C1 OHTBGMREZYLZQD-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 235000015429 Mirabilis expansa Nutrition 0.000 description 2
- 244000294411 Mirabilis expansa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000311 effect on hepatitis Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000013536 miso Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 241000208223 Anacardiaceae Species 0.000 description 1
- 244000226021 Anacardium occidentale Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000209524 Araceae Species 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 241000218791 Ginkgoaceae Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 241001113425 Iridaceae Species 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 241000208476 Primulaceae Species 0.000 description 1
- 241000208465 Proteaceae Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000020226 cashew nut Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 235000020888 liquid diet Nutrition 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 238000012335 pathological evaluation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Birds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Description
5-ヘプチルレゾルシノール[又は1,3-ジヒドロキシ-5-n-ヘプチルベンゼン(C7:0)]
5-ノニルレゾルシノール[又は1,3-ジヒドロキシ-5-n-ノニルベンゼン(C9:0)]
5-ウンデシルレゾルシノール[又は1,3-ジヒドロキシ-5-n-ウンデシルベンゼン(C11:0)]
5-トリデシルレゾルシノール[又は1,3-ジヒドロキシ-5-n-トリデシルベンゼン(C13:0)]
5-ペンタデシルレゾルシノール[又は1,3-ジヒドロキシ-5-n-ペンタデシルベンゼン(C15:0)]
5-ヘプタデシルレゾルシノール[又は1,3-ジヒドロキシ-5-n-ヘプタデシルベンゼン(C17:0)]
5-ノナデシルレゾルシノール[又は1,3-ジヒドロキシ-5-n-ノナデシルベンゼン(C19:0)]
5-ヘンイコシルレゾルシノール[又は1,3-ジヒドロキシ-5-n-ヘンイコシルベンゼン(C21:0)]
5-トリコシルレゾルシノール[又は1,3-ジヒドロキシ-5-n-トリコシルベンゼン(C23:0)]
5-ペンタコシルレゾルシノール[又は1,3-ジヒドロキシ-5-n-ペンタコシルベンゼン(C25:0)]
5-ヘプタコシルレゾルシノール[又は1,3-ジヒドロキシ-5-n-ヘプタコシルベンゼン(C27:0)]
ライ麦ふすま(約9.4kg)を減圧乾燥し(80℃、16時間)、乾燥した原料に対し5倍量の99%エタノールを添加し、加温下に撹拌抽出した(60℃、1時間)。その後、固液分離して濾液Aを得、その残渣には等倍量の99%エタノールを添加し、更にリンス後に固液分離して濾液Bを得た。得られた濾液Aと濾液Bを合わせ、減圧濃縮して、ライ麦ふすまエタノール抽出物516gを得た。
調製例1で得られた乾固物中のアルキルレゾルシノール量を高速液体クロマトグラフィーによる分析法で定量した。なお、以下、アルキルレゾルシノールのことを「ARs」又は「AR」という場合がある。
非アルコール性脂肪肝炎モデルマウス(日本チャールス・リバー社製、C57BL/6NASHマウス雄)を6週齢の時点で搬入後、2日間の馴化期間を経て、1ケージあたり6匹飼育した。マウスの飼育は、12時間間隔の明暗サイクル(明期:午前8時-午後20時)で維持された恒温・恒湿室で行い、馴化期間後、下記に示す各試験群に応じた飼料を自由摂取させた。
・レスベラトロール摂取群(R群):レスベラトロール(東京化成工業株式会社)を0.4質量%配合した飼料
・ARs高摂取群(AH群):ARsを0.9質量%配合した飼料
・ARs低摂取群(AL群):ARsを0.3質量%配合した飼料
肝臓機能の一般的な指標である血漿中のアスパラギン酸アミノトランスフェラーゼ(AST)値とアラニンアミノトランスフェラーゼ(ALT)値を測定した。測定は、トランスアミナーゼCII-テストワコー(富士フィルム和光純薬社製)を用いて、同社説明書に従い実施した。
凍結肝臓組織50mgをチューブに入れ、これに、クロロホルムとメタノールをそれぞれ2:1の液量割合で含む混液1mLを添加した。ホモジナイザーでペースト状になるまで粉砕し、全混合物を室温で15-20分間シェーカーを用いて撹拌した。ホモジネートを15000rpmで5分間遠心分離し、上清を回収した。回収した上清に生理用食塩水0.5mLを添加し、数秒間混合した。混合物を2000rpmで1分間遠心分離し、上部相を除去する操作を2回繰り返した。下部クロロホルム相を減圧乾燥し、乾固物をエタノールで100μLずつ懸濁し、エタノールに45μLずつ添加して混合した。これをサンプルとして、中性脂肪量を測定した。
凍結肝臓組織をパラフィン包埋し、スライスした。作製した切片について、常法により、ヘマトキシリン・エオジン(HE)染色を行った。各群の肝臓組織のHE染色の結果を図6に示す。
ペルオキシソーム増殖因子活性化受容体γ(Peroxisome Proliferators-Activated Receptorγ)(PPARγ)は核内受容体スーパーファミリーに属するタンパク質で脂質代謝に重要な働きを示すことが知られている。このPPARγのリガンドであるピオグリタゾン(糖尿病薬として応用されている)は、非アルコール性肝炎治療薬としても有効である。このことから、PPARγの機能増強が、非アルコール性肝炎治療約の有用な標的であると考えられた。そこで本試験例では、肝臓組織中のPPARγ遺伝子の発現量を調べた。具体的には、以下のようにして定量PCRにより測定した。
フォワード:5’-TGTCGGTTTCAGAAGTGCCTTG-3’(配列番号1)
リバース:5’-TTCAGCTGGTCGATATCACTGGAG-3’ (配列番号2)
(βアクチン用)
フォワード:5’-TGACAGGATGCAGAAGGAGA-3’ (配列番号3)
リバース:5’-GCTGGAAGGTGGACAGTGAG-3’ (配列番号4)
(95℃ 30秒→95℃ 5秒→60℃ 30秒)×40サイクル→95℃60秒
脂質代謝に重要な働きを示すことが知られている、ペルオキシソーム増殖因子活性化受容体コアクチベータ1α(Peroxisome Proliferators-Activated Receptor γ Coactivator-1α)(PGC-1α)、ペルオキシソーム増殖因子活性化受容体α(Peroxisome Proliferators-Activated Receptor PPARα)、アジポネクチン(Adiponectin)の各種遺伝子について、肝臓組織中の遺伝子発現量を調べた。測定は、試験例6と同様にして定量PCRにより行った。そのためのプライマーは下記配列を使用した。
フォワード:5’-AAGTGTGGAACTCTCTGGAACTG-3’(配列番号5)
リバース:5’-GGGTTATCTTGGTTGGCTTTATG-3’ (配列番号6)
(PPARα用)
フォワード:5’-AAGTGCCTGTCTGTCGGGATG-3’(配列番号7)
リバース:5’-CCAGAGATTTGAGGTCTGCAGTTTC-3’ (配列番号8)
(アジポネクチン用)
フォワード:5’-GTCAGTGGATCTGACGACACCAA-3’(配列番号9)
リバース:5’-ATGCCTGCCATCCAACCTG-3’ (配列番号10)
(βアクチン用)
フォワード:5’-TGACAGGATGCAGAAGGAGA-3’ (配列番号3)
リバース:5’-GCTGGAAGGTGGACAGTGAG-3’ (配列番号4)
(95℃ 30秒→95℃ 5秒→60℃ 30秒)×40サイクル→95℃60秒
試験例7においてアルキルレゾルシノール摂取群で遺伝子発現量が増加していることが確認されたPGC-1αは、その遺伝子発現増強によって、ミトコンドリア数の上昇、酸化的リン酸化の促進、TCAサイクルの活性化、β酸化による脂質燃焼促進、糖新生、ケトン体合成促進などがもたらされることが知られている。
フォワード:5’-AACCCCGCTCTACCTCACC-3’(配列番号11)
リバース:5’-GTAGCCCATTTCTTCCCATTT-3’ (配列番号12)
(ゲノムDNA用)
フォワード:5’-CGCGGTTCTATTTTGTTGGT-3’ (配列番号13)
リバース:5’-AGTCGGCATCGTTTATGGTC-3’ (配列番号14)
(95℃ 30秒→95℃ 5秒→60℃ 30秒)×40サイクル→95℃60秒
Claims (18)
- 植物由来のレゾルシノール性脂質を有効成分とし、肝炎の症状を改善するために用いられる、肝臓機能改善用組成物。
- 前記レゾルシノール性脂質は、アルキルレゾルシノールである、請求項1記載の肝臓機能改善用組成物。
- 前記レゾルシノール性脂質は、イネ科植物由来である、請求項1又は2記載の肝臓機能改善用組成物。
- 前記レゾルシノール性脂質は、小麦及び/又はライ麦の糟糠類及び/又は全穀粒由来である、請求項1~3のいずれか1項に記載の肝臓機能改善用組成物。
- レゾルシノール性脂質を含有する植物の溶媒抽出物からなる、請求項1~4のいずれか1項に記載の肝臓機能改善用組成物。
- 前記溶媒がエタノール及び/又はヘキサンである、請求項5記載の肝臓機能改善用組成物。
- 非アルコール性肝炎の症状を改善するために用いられる、請求項1~6のいずれか1項に記載の肝臓機能改善用組成物。
- 非アルコール性肝炎による肝臓の中性脂肪蓄積を抑制するために用いられる、請求項7記載の肝臓機能改善用組成物。
- 飲食品、食品添加物、医薬品、サプリメント、又は動物飼料として提供される、請求項1~8のいずれか1項に記載の肝臓機能改善用組成物。
- 肝炎の症状を改善するために用いられる、肝臓機能改善用組成物の調製のための植物由来のレゾルシノール性脂質の使用。
- 前記レゾルシノール性脂質は、アルキルレゾルシノールである、請求項10記載の使用。
- 前記レゾルシノール性脂質は、イネ科植物由来である、請求項10又は11記載の使用。
- 前記レゾルシノール性脂質は、小麦及び/又はライ麦の糟糠類及び/又は全穀粒由来である、請求項10~12のいずれか1項に記載の使用。
- 前記肝臓機能改善用組成物は、レゾルシノール性脂質を含有する植物の溶媒抽出物からなる、請求項10~13のいずれか1項に記載の使用。
- 前記溶媒がエタノール及び/又はヘキサンである、請求項14記載の使用。
- 前記肝臓機能改善用組成物は、非アルコール性肝炎の症状を改善するために用いられる、請求項10~15のいずれか1項に記載の使用。
- 前記肝臓機能改善用組成物は、非アルコール性肝炎による肝臓の中性脂肪蓄積を抑制するために用いられる、請求項16記載の使用。
- 前記肝臓機能改善用組成物は、飲食品、食品添加物、医薬品、サプリメント、又は動物飼料として提供される、請求項10~17のいずれか1項に記載の使用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023132389A JP2023157951A (ja) | 2019-05-22 | 2023-08-15 | 肝臓機能改善用組成物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019095658 | 2019-05-22 | ||
JP2019095658 | 2019-05-22 | ||
PCT/JP2020/019742 WO2020235546A1 (ja) | 2019-05-22 | 2020-05-19 | 肝臓機能改善用組成物 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023132389A Division JP2023157951A (ja) | 2019-05-22 | 2023-08-15 | 肝臓機能改善用組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JPWO2020235546A1 JPWO2020235546A1 (ja) | 2020-11-26 |
JPWO2020235546A5 JPWO2020235546A5 (ja) | 2022-05-17 |
JP7333815B2 true JP7333815B2 (ja) | 2023-08-25 |
Family
ID=73459385
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021520792A Active JP7333815B2 (ja) | 2019-05-22 | 2020-05-19 | 肝臓機能改善用組成物 |
JP2023132389A Pending JP2023157951A (ja) | 2019-05-22 | 2023-08-15 | 肝臓機能改善用組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023132389A Pending JP2023157951A (ja) | 2019-05-22 | 2023-08-15 | 肝臓機能改善用組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220323372A1 (ja) |
EP (1) | EP3974026A4 (ja) |
JP (2) | JP7333815B2 (ja) |
CN (1) | CN113873895A (ja) |
TW (1) | TWI830917B (ja) |
WO (1) | WO2020235546A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021016363A (ja) * | 2019-07-23 | 2021-02-15 | 株式会社日清製粉グループ本社 | 脂質分解促進剤及びこれを含む飲食品、並びに脂質分解促進用加工食品 |
US11614771B2 (en) | 2020-11-25 | 2023-03-28 | Qubit Moving And Storage, Llc | Method for synchronizing and locking clocks |
CN115557830B (zh) * | 2022-10-26 | 2024-02-13 | 江南大学 | 基于超声辅助酶解法提取小麦麸皮中烷基间苯二酚的方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014139166A (ja) | 2012-12-20 | 2014-07-31 | National Institute Of Advanced Industrial & Technology | 耐糖能異常改善剤 |
WO2015193962A1 (ja) | 2014-06-17 | 2015-12-23 | 独立行政法人産業技術総合研究所 | 耐糖能異常改善剤 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2555076C2 (de) | 1975-12-06 | 1986-03-20 | Henkel KGaA, 4000 Düsseldorf | Kontinuierliches Verfahren zum Bleichen saurer α-Sulfofettsäureester |
JPS5951448B2 (ja) | 1980-03-17 | 1984-12-14 | 株式会社日立製作所 | 台車けん引形無人運搬車 |
JP2613474B2 (ja) | 1989-03-25 | 1997-05-28 | サンスター株式会社 | 口腔用抗菌剤組成物 |
RU2405562C1 (ru) * | 2009-07-24 | 2010-12-10 | Тихоокеанский океанологический институт им. В.И. Ильичева Дальневосточного отделения Российской академии наук (ТОИ ДВО РАН) | Средство, обладающее гепатопротекторным действием |
JP2013091612A (ja) | 2011-10-25 | 2013-05-16 | Nisshin Seifun Group Inc | 免疫抑制剤 |
JP6144564B2 (ja) | 2013-07-23 | 2017-06-07 | 株式会社日清製粉グループ本社 | 炎症予防剤 |
JP6460402B2 (ja) | 2014-05-16 | 2019-01-30 | 国立研究開発法人産業技術総合研究所 | コレステロール排出促進用医薬組成物又は食品組成物 |
JP2015218130A (ja) | 2014-05-16 | 2015-12-07 | 国立研究開発法人産業技術総合研究所 | 腸内フローラ調整能を有するイネ科植物抽出物 |
JP2016132641A (ja) | 2015-01-20 | 2016-07-25 | 国立研究開発法人産業技術総合研究所 | 食品の摂取方法 |
JP6516259B2 (ja) | 2015-02-12 | 2019-05-22 | 国立研究開発法人産業技術総合研究所 | 睡眠改善剤 |
CN105566492A (zh) * | 2016-01-16 | 2016-05-11 | 深圳市贝沃德克生物技术研究院有限公司 | 抗乙肝表面抗原的荧光抗体的制备方法 |
US10307388B2 (en) * | 2016-12-29 | 2019-06-04 | The United States Of America As Represented By The Secretary Of The Navy | Compositions and methods for diagnosis and treatment of inflammation |
-
2020
- 2020-05-19 WO PCT/JP2020/019742 patent/WO2020235546A1/ja active Search and Examination
- 2020-05-19 EP EP20809751.9A patent/EP3974026A4/en active Pending
- 2020-05-19 JP JP2021520792A patent/JP7333815B2/ja active Active
- 2020-05-19 CN CN202080037969.XA patent/CN113873895A/zh active Pending
- 2020-05-19 US US17/607,950 patent/US20220323372A1/en active Pending
- 2020-05-21 TW TW109116941A patent/TWI830917B/zh active
-
2023
- 2023-08-15 JP JP2023132389A patent/JP2023157951A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014139166A (ja) | 2012-12-20 | 2014-07-31 | National Institute Of Advanced Industrial & Technology | 耐糖能異常改善剤 |
WO2015193962A1 (ja) | 2014-06-17 | 2015-12-23 | 独立行政法人産業技術総合研究所 | 耐糖能異常改善剤 |
Non-Patent Citations (1)
Title |
---|
Sci. Rep.,2017年,7:43679,pp.1-8 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2020235546A1 (ja) | 2020-11-26 |
WO2020235546A1 (ja) | 2020-11-26 |
CN113873895A (zh) | 2021-12-31 |
JP2023157951A (ja) | 2023-10-26 |
US20220323372A1 (en) | 2022-10-13 |
EP3974026A1 (en) | 2022-03-30 |
TWI830917B (zh) | 2024-02-01 |
TW202110427A (zh) | 2021-03-16 |
EP3974026A4 (en) | 2023-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7333815B2 (ja) | 肝臓機能改善用組成物 | |
JP6745250B2 (ja) | モリンガエキス | |
JP4179494B2 (ja) | ペルオキシソーム増殖剤応答性受容体リガンド剤 | |
EP2992933B1 (en) | Ginsenoside f2 for prophylaxis and treatment of liver disease | |
JP2017200951A (ja) | 黒ショウガ成分含有組成物 | |
JP2011157343A (ja) | 抗老化経口剤 | |
WO2007001080A1 (ja) | ビワ葉抽出物を含有する飲食品及び医薬品 | |
JP2013071909A (ja) | 脳内過酸化脂質蓄積抑制剤 | |
JP2011207776A (ja) | アディポネクチン産生促進剤 | |
KR20060119706A (ko) | 생활 습관병 예방ㆍ개선용의 유지 가공 조성물 | |
JP5926616B2 (ja) | 老化抑制剤 | |
WO2015193962A1 (ja) | 耐糖能異常改善剤 | |
JP2016132641A (ja) | 食品の摂取方法 | |
JP2008137976A (ja) | 脂肪蓄積抑制剤 | |
JP5969529B2 (ja) | 抗炎症剤 | |
JP5590758B2 (ja) | マーカータンパク質量調節用組成物 | |
JP5981088B2 (ja) | エネルギー消費促進剤 | |
JP7376335B2 (ja) | 脂質異常症の予防、改善又は治療用組成物 | |
JP4494198B2 (ja) | 膵リパーゼ阻害剤、脂肪分解抑制剤、及び、脂肪肝予防剤又は治療剤 | |
JP7242219B2 (ja) | 血糖値上昇抑制剤、糖尿病抑制剤、及び食品組成物 | |
KR100992995B1 (ko) | 피페로날의 신규한 용도 | |
WO2006106705A1 (ja) | 発癌抑制用油脂含有組成物 | |
JP6241631B2 (ja) | 経口用組成物 | |
JP2016123276A (ja) | 非アルコール性脂肪性肝疾患の発症リスクを低減する機能を有する食品 | |
JP2023069459A (ja) | サイクリックampホスホジエステラーゼ活性阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A5211 Effective date: 20211111 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220607 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230613 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230703 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230718 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230815 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7333815 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |